| Autor: |
Hokland P; Immunhaematologisk Laboratorium, Haematologisk Afdeling R, Arhus Universitetshospital, Arhus Sygehus, DK-8000 Arhus C. phokland@ki.au.dk, Nyvold CG, Stentoft J, Ommen HB, Ebbesen LH, Braendstrup K, Andersen BL, Mikkelsen LS, Ostergaard M |
| Jazyk: |
dánština |
| Zdroj: |
Ugeskrift for laeger [Ugeskr Laeger] 2009 Jan 19; Vol. 171 (4), pp. 229-31. |
| Abstrakt: |
In haematological malignancies, molecular markers like fusion DNA from balanced translocations, point mutations, or over-expressed genes can now be used not only for diagnosis, but also for determination of the minimal residual disease (MRD) after cytoreduction with a sensitivity by far exceeding that of previous methodologies. The sensitivity of quantitative polymerase chain reaction typically reaches a validated identification of 1 malignant cell in 100,000. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
